Abstract
Background: Adult-onset Still’s disease (AOSD) is a challenging diagnosis because of the variability in clinical presentation and lack of gold-standard diagnostic investigations. Even after diagnosis, the treatment is challenging, especially when the disease is refractory to first-line therapy. Multiple pharmacotherapeutic options exist for refractory AOSD, but treatment failures still occur. Etanercept, a Tumor necrosis factor (TNF)-alpha inhibitor, is one of the options that has been rarely used for refractory AOSD, with various outcomes ranging from no response to complete remission.
Case Presentation: In this case, we highlight how a previously healthy lady had refractory AOSD to glucocorticoids, methotrexate, and hydroxychloroquine combination therapy. There was no response to interleukin (IL)-1 therapy, which necessitated a switch to a combination of etanercept, low-dose methotrexate, and low-dose glucocorticoids with complete remission for a total of three- -year follow-up.
Conclusion: The combination of methotrexate and Etanercept can maintain remission in patients with refractory AOSD.
Graphical Abstract
[1]
Kadavath S, Efthimiou P. Adult-onset Still’s disease-pathogenesis, clinical manifestations, and new treatment options. Ann Med 2015; 47(1): 6-14.
[http://dx.doi.org/10.3109/07853890.2014.971052] [PMID: 25613167]
[http://dx.doi.org/10.3109/07853890.2014.971052] [PMID: 25613167]
[2]
Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still’s disease. J Autoimmun 2018; 93: 24-36.
[http://dx.doi.org/10.1016/j.jaut.2018.07.018] [PMID: 30077425]
[http://dx.doi.org/10.1016/j.jaut.2018.07.018] [PMID: 30077425]
[3]
Castañeda S, Blanco R, González-Gay MA. Adult-onset Still’s disease: Advances in the treatment. Best Pract Res Clin Rheumatol 2016; 30(2): 222-38.
[http://dx.doi.org/10.1016/j.berh.2016.08.003] [PMID: 27886796]
[http://dx.doi.org/10.1016/j.berh.2016.08.003] [PMID: 27886796]
[4]
Jamilloux Y, Gerfaud-Valentin M, Henry T, Sève P. Treatment of adult-onset Still’s disease: A review. Ther Clin Risk Manag 2014; 11: 33-43.
[PMID: 25653531]
[PMID: 25653531]
[5]
Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P. Adult-onset still’s disease. Autoimmun Rev 2014; 13(7): 708-22.
[http://dx.doi.org/10.1016/j.autrev.2014.01.058] [PMID: 24657513]
[http://dx.doi.org/10.1016/j.autrev.2014.01.058] [PMID: 24657513]
[6]
Kong X, Xu D, Zhang W, Zhao Y, Zeng X, Zhang F. Clinical features and prognosis in adult-onset still’s disease: A study of 104 cases. Clin Rheumatol 2010; 29(9): 1015-9.
[http://dx.doi.org/10.1007/s10067-010-1516-1] [PMID: 20549276]
[http://dx.doi.org/10.1007/s10067-010-1516-1] [PMID: 20549276]
[7]
Mitamura M, Tada Y, Koarada S, et al. Cyclosporin A treatment for Japanese patients with severe adult-onset Still’s disease. Mod Rheumatol 2009; 19(1): 57-63.
[http://dx.doi.org/10.3109/s10165-008-0126-0] [PMID: 18839270]
[http://dx.doi.org/10.3109/s10165-008-0126-0] [PMID: 18839270]
[8]
Vignes S, Wechsler B, Amoura Z, et al. Intravenous immunoglobulin in adult Still’s disease refractory to non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol 1998; 16(3): 295-8.
[PMID: 9631752]
[PMID: 9631752]
[9]
Kalyoncu U, Solmaz D, Emmungil H, et al. Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still’s disease: Data from a large multicenter cohort. J Autoimmun 2016; 69: 59-63.
[http://dx.doi.org/10.1016/j.jaut.2016.02.010] [PMID: 26970681]
[http://dx.doi.org/10.1016/j.jaut.2016.02.010] [PMID: 26970681]
[10]
Efthimiou P, Kontzias A, Hur P, Rodha K, Ramakrishna GS, Nakasato P. Adult-onset Still’s disease in focus: Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies. Semin Arthritis Rheum 2021; 51(4): 858-74.
[http://dx.doi.org/10.1016/j.semarthrit.2021.06.004] [PMID: 34175791]
[http://dx.doi.org/10.1016/j.semarthrit.2021.06.004] [PMID: 34175791]
[11]
Laskari K, Tektonidou MG, Katsiari C, et al. Outcome of refractory to conventional and/or biologic treatment adult Still’s disease following canakinumab treatment: Countrywide data in 50 patients. Semin Arthritis Rheum 2021; 51(1): 137-43.
[http://dx.doi.org/10.1016/j.semarthrit.2020.10.011] [PMID: 33383289]
[http://dx.doi.org/10.1016/j.semarthrit.2020.10.011] [PMID: 33383289]
[12]
Yoo DH. Biologics for the treatment of adult-onset still’s disease. Expert Opin Biol Ther 2019; 19(11): 1173-90.
[http://dx.doi.org/10.1080/14712598.2019.1652591] [PMID: 31379214]
[http://dx.doi.org/10.1080/14712598.2019.1652591] [PMID: 31379214]
[13]
Vercruysse F, Barnetche T, Lazaro E, et al. Adult-onset Still’s disease biological treatment strategy may depend on the phenotypic dichotomy. Arthritis Res Ther 2019; 21(1): 53.
[http://dx.doi.org/10.1186/s13075-019-1838-6] [PMID: 30755262]
[http://dx.doi.org/10.1186/s13075-019-1838-6] [PMID: 30755262]
[14]
Kuek A, Weerakoon A, Ahmed K, Ostör AJK. Adult-onset Still’s disease and myocarditis: Successful treatment with intravenous immunoglobulin and maintenance of remission with etanercept. Rheumatology 2007; 46(6): 1043-4.
[http://dx.doi.org/10.1093/rheumatology/kem066] [PMID: 17449487]
[http://dx.doi.org/10.1093/rheumatology/kem066] [PMID: 17449487]
[15]
Asherson RA, Pascoe L. Adult onset Still’s disease: Response to enbrel. Ann Rheum Dis 2002; 61(9): 859-a-60.
[http://dx.doi.org/10.1136/ard.61.9.859-a] [PMID: 12176823]
[http://dx.doi.org/10.1136/ard.61.9.859-a] [PMID: 12176823]
[16]
Serratrice J, Granel B, Disdier P, Weiller PJ, Dussol B. Resolution with etanercept of nephrotic syndrome due to renal AA amyloidosis in adult Still’s disease. Am J Med 2003; 115(7): 589-90.
[http://dx.doi.org/10.1016/j.amjmed.2003.04.001] [PMID: 14599647]
[http://dx.doi.org/10.1016/j.amjmed.2003.04.001] [PMID: 14599647]
[17]
Woo H, Kim OK, Lee GH, Park JJ, Lee SS, Park YW. Successful treatment with etanercept in a patient with adult-onset still’s disease. J Rheum Dis 2006; 13(4): 306-10.
[18]
Yang DH, Chang DM, Lai JH, et al. Etanercept as a rescue agent in patient with adult onset Still’s disease complicated with congestive heart failure. Rheumatol Int 2008; 29(1): 95-8.
[http://dx.doi.org/10.1007/s00296-008-0619-3] [PMID: 18500457]
[http://dx.doi.org/10.1007/s00296-008-0619-3] [PMID: 18500457]
[19]
Husni ME, Maier AL, Mease PJ, et al. Etanercept in the treatment of adult patients with Still’s disease. Arthritis Rheum 2002; 46(5): 1171-6.
[http://dx.doi.org/10.1002/art.10231] [PMID: 12115220]
[http://dx.doi.org/10.1002/art.10231] [PMID: 12115220]
[20]
Fautrel B, Sibilia J, Mariette X, Combe B. Tumour necrosis factor blocking agents in refractory adult Still’s disease: An observational study of 20 cases. Ann Rheum Dis 2005; 64(2): 262-6.
[http://dx.doi.org/10.1136/ard.2004.024026] [PMID: 15184196]
[http://dx.doi.org/10.1136/ard.2004.024026] [PMID: 15184196]
[21]
Franchini S, Dagna L, Salvo F, Aiello P, Baldissera E, Sabbadini MG. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still’s disease. Arthritis Rheum 2010; 62(8): 2530-5.
[http://dx.doi.org/10.1002/art.27532] [PMID: 20506370]
[http://dx.doi.org/10.1002/art.27532] [PMID: 20506370]
[22]
Suematsu R, Ohta A, Matsuura E, et al. Therapeutic response of patients with adult Still’s disease to biologic agents: Multicenter results in Japan. Mod Rheumatol 2012; 22(5): 712-9.
[http://dx.doi.org/10.3109/s10165-011-0569-6] [PMID: 22160845]
[http://dx.doi.org/10.3109/s10165-011-0569-6] [PMID: 22160845]
[23]
Kumari R, Uppal SS. Prolonged remission in adult-onset Still’s disease with etanercept. Clin Rheumatol 2006; 25(1): 106-8.
[http://dx.doi.org/10.1007/s10067-004-1064-7] [PMID: 15856368]
[http://dx.doi.org/10.1007/s10067-004-1064-7] [PMID: 15856368]
[24]
Rech J, Ronneberger M, Englbrecht M, et al. Successful treatment of adult-onset Still’s disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade. Ann Rheum Dis 2011; 70(2): 390-2.
[http://dx.doi.org/10.1136/ard.2010.129403] [PMID: 20650873]
[http://dx.doi.org/10.1136/ard.2010.129403] [PMID: 20650873]
Related Books
Natural Products for the Management of Arthritic Disorders
